CT-guided Interstitial Implantation of ~(125)I Seed for Lung Cancer

Wang Junjie,Yuan Huishu,Wang Hao
2008-01-01
Abstract:Objective To investigate the feasibility and short-term efficacy of CT-guided interstitial implantation of 125I seeds for lung cancer. Methods Under local anesthesia, 16 patients with lung cancer were treated with CT-guided interstitial implantation of 125I seeds. The TPS was used to calculate the number of seeds, the space distribution, and the number of needles. The MPD of 125I seed implantation were 90-110 Gy for patients who had ever received external radiotherapy and 140-160 Gy for those who had never received external irradiation. The PTV included CTV plus 1 cm margin. The activity of each seed was 0.40-0.70 mCi. A median of 38 (range, 15-145) 125I seeds were implanted, and CT scan were performed after the operation to evaluate the quality of the operation. Three of the patients received 3D-CRT external beam radiation therapy at a total dose of 45-50 Gy. Results The patients were followed up for a median of 14 months (6-47 months), during which none of them had serious operation-related complications. All patients could well tolerated seed implantation. The 1-and 2-year local control rates were 93.8% (15/16) and 93.8% (15/16), respectively. The median survival time was 14 months (6-24 months),and the 1-and 2-year survival rates were 62.5% (10/16) and 37.5% (6/16), respectively. Among the patients, 6 cases died of systemic metastasis, 3 died of cachexia, and 1 died of cerebral hemorrhage. Conclusions CT-guided interstitial implantation of 125I seeds is a safe and minimally invasive method for lung cancer with a low rate of complications and good outcomes. The efficacy of the treatment might be improved by combining with external radiotherapy and systemic chemotherapy.
What problem does this paper attempt to address?